Ultragenyx Pharmaceutical Inc.: Miss — EPS -$1.16, Revenue $173M
Earnings MissQ3 2026 · After-market
Did Ultragenyx Pharmaceutical Inc. (RARE) beat earnings today?
No, Ultragenyx Pharmaceutical Inc. (RARE) missed Wall Street analyst expectations for Q3 2026, reporting lower-than-expected EPS and lower-than-expected revenue.
Earnings Per Share-13.73% surprise
-$1.16Actual
Expected: -$1.02
vs. year ago +42.9%
Total Revenue-5.83% surprise
$173MActual
Expected: $183.71M
vs. year ago +8.1%
Released Nov 03 · 4:01 PM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $173.00M | $160.00M | +8.1% |
| Revenue detail — reported lines | |||
| └─CRYSVITA Revenue | $109.00M | $112.00M | -2.7% |
| └─Product sales - Latin America and Türkiye | $41.00M | $47.00M | -12.8% |
| └─Royalty revenue - U.S. and Canada | $61.00M | $57.00M | +7.0% |
| └─Royalty revenue - Europe | $7.00M | $8.00M | -12.5% |
| └─DOJOLVI | $30.00M | $24.00M | +25.0% |
| └─EVKEEZA | $24.00M | $17.00M | +41.2% |
| └─MEPSEVII | $10.00M | $7.00M | +42.9% |
| Net Loss | ($118.00M) | ($180.00M) | - |
| GAAP Basic and Diluted EPS | -$1.16 | -$1.81 | - |
Financial Outlook / Guidance
| Metric | FY26 Outlook | FY27 Outlook | |
|---|---|---|---|
| Guidance | Expected | Guidance | |
| Total revenue | $730M-$760M | $760.21MMiss -2.00% | — |
| Crysvita revenue | $500M-$520M | — | — |
| Dojolvi revenue | $100M-$110M | — | — |
| R&D expenses | — | — | <$350M |
| SG&A expenses | — | — | <$375M |
FY26 Outlook
- Total revenue
- Guidance$730M-$760MExpected$760.21MMiss -2.00%
- Crysvita revenue
- Guidance$500M-$520MExpected—
- Dojolvi revenue
- Guidance$100M-$110MExpected—
- R&D expenses
- Guidance—Expected—
- SG&A expenses
- Guidance—Expected—
FY27 Outlook
- Total revenue
- Guidance—
- Crysvita revenue
- Guidance—
- Dojolvi revenue
- Guidance—
- R&D expenses
- Guidance<$350M
- SG&A expenses
- Guidance<$375M
Business Highlights
- ➤FDA granted accelerated approval for GENGLYCOS in GSDIa patients aged eight and older.
- ➤FDA granted full approval for FAYUVI for pediatric Sanfilippo syndrome Type A.
- ➤Entered agreements to sell two PRVs for a combined $413M.
- ➤Completed sale of the GENGLYCOS PRV for $210M.
- ➤Agreed to sell the FAYUVI PRV for $203M.
- ➤Initiated approximately 20% headcount reduction to a workforce of approximately 1,000 employees.
- ➤Wind-down underway for all ongoing GTX-102 Angelman syndrome studies.
- ➤Terminating UX701 Wilson disease program after study goals were not achieved.
- ➤UX016 Phase 1/2 program is fully funded through clinical proof-of-concept by a patient group.
- ➤DTX301 Phase 3 Enh3ance study continues through 64-week follow-up.
- ➤UX143 Phase 3 analyses were presented at the ASBMR 2026 Annual Meeting.
Management Commentary
Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx
“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products. With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”